Oncology

19 Sep 2017

757
(96 votes)

How Effectiveness of Rigvir® for Prostate Cancer Can Be Measured

The very first thing you should know about Rigvir® is the fact that it’s the first registered virotherapy medicine. Virotherapy for cancer is a treatment method with a virus being the key component of the healing process. Rigvir®, deriving from Riga virus, is ECHO-7 virus, originally detected in babies’ intestines. It has cancer treatment capacity, which was discovered in the 1950-60s in Latvia.

rigvir prostate cancer

Rigvir® was developed in the 1950s, and since then virotherapy has become more popular with cancer patients

The operating principle of Rigvir® is fully focused on the destruction of malignant cells and having no influence on healthy ones. Once you get a Rigvir® injection to cure prostate cancer, the virus roams your body in search of tumors. Cell by cell, it destroys the malignancy affecting the metastases in the same way. 


Your body temperature can rise to 37.5°C/99.5°F, but it’s the only one side effect you may have. Unlike chemo, your organism doesn’t suffer after virotherapy for prostate cancer. The healthy cells don’t get affected.

Since Rigvir® invention a range of clinical studies was conducted. Rigvir® positive influence on survival rates is briefly summarized in the following graphs [2]:

rigvir prostate cancer

rigvir prostate cancer

rigvir prostate cancer

rigvir prostate cancer 

The first trials were made with melanoma patients, who claimed Rigvir® improved their health [1]. And the most recent studies published in Melanoma Research, a specialized journal, in 2015 admit that Rigvir® boosts survival rates in 4-6 times for those who apply it [3]. Except for skin and prostate cancer, Rigvir® can also treat a number of other conditions including prostate cancer. Below in STEP 1 you can find the full list of Rigvir sensitive dignoses while STEP 2 features medical reports you should submit to qualify for Rigvir therapy.

If you’re interested in matters of legislation, you should know that the drug was registered in Latvia in 2005. Since then two more countries succeeded in making it legal – Georgia (2015) and neighboring Armenia (2016). Still, Latvia is the motherland of virotherapy and the hub for Rigvir sale. That’s why most patients and doctors who are enthusiastic about Rigvir® treatment visit this state to complete trainings and share the knowledge with the colleagues back home. For comparison, read about Rigvir in Mexico and Latvia.

Before checking whether you can qualify for this kind of treatment, please collect your medical files. As your case differs from others and might have certain distinguishable features, an oncologist first has to evaluate your case. The assessment is made at no charge and you receive the medical opinion regarding your case within 48-72 hours after you submit your medical files.

If you would like to know whether you or someone you know can benefit from Rigvir® therapy as well as how much it is going to cost, click the button below.

 


 

List of References

  1. Brūvere, R., O., Heisele A. Ferdats, A. Rupais, and A. Muceniece, Echovirus-mediated biotherapy for malignant tumours: 40 years of investigation. Acta medica Lituanica, 2002. Suppl. 9: p. 97-100.
  2. “Adapted ECHO-7 Virus RigVir Immunotherapy (oncolytic Virotherapy) Prolongs Survival in Melanoma Patients after Surgical Excision of the Tumour in a Retrospective Study.” Doniņa, Simona; Strēle, Ieva; Proboka, Guna; Auziņš, Jurgis; Alberts, Pēteris; Jonsson, Björn; Venskus, Dite; Muceniece, Aina. Melanoma Research: October 2015 - Volume 25 - Issue 5 - p 421–426.
  3. Alberts, P., E. Olmane, L. Brokāne, Z. Krastiņa, M. Romanovska, K. Kupčs, S. Isajevs, G. Proboka, R. Erdmanis, J. Nazarovs, and D. Venskus, Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports. APMIS, 2016. 124(10): p. 896-904.